Studying Biomarkers in Diagnosing Cervical Lesions in Patients with Abnormal Cervical Cells

Overview

Información sobre este estudio

This clinical trial is studying biomarkers in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Patients with a cytologic diagnosis of AGC (AGC, AEC, AEmC) or a cytologic/histologic diagnosis of AIS documented within the last 6 months who can wait at least one week after the AGC or AIS diagnosis to have an LBC specimen collected (within two weeks of registration) and then receive any other intervention.
  • Patients with positive HPV results who are willing to undergo a complete histologic examination of the uterus and cervix, including the cervical transformation zone, within 6 months of the AGC or AIS diagnosis (histologic examination includes a LEEP, LETZ, excisional cone biopsy, or hysterectomy).
  • Patients who are 18 years of age or older.
  • Patients must have signed an approved informed consent and authorization permitting release of personal health information.

Exclusion Criteria:

  • Patients under 18 years of age.
  • Patients who have had a hysterectomy.
  • Patients with a history of cancer of the endometrium, vagina, or cervix. 
  • Patients who have previously been treated, or are currently being treated with radiation therapy or chemotherapy for vaginal or cervical cancer.
  • Patients who are known to be HIV-positive, as these patients often have disease that is highly variable and aggressive resulting in rapid changes.
  • Patients who are pregnant and thought to be at risk for excessive bleeding or preterm labor if a cone biopsy is performed.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Andrea Wahner Hendrickson, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20116123

Mayo Clinic Footer